التفاصيل البيبلوغرافية
| العنوان: |
Antifungal prophylaxis with nebulized amphotericin-B in solid-organ transplant recipients with severe COVID-19: a retrospective observational study |
| المؤلفون: |
Rombauts, Alexander, Bodro, Marta, Daniel Gumucio, Victor, Carbonell, Irene, Favà, Àlex, Lladó, Laura, González-Costello, José, Oppenheimer, Federico, Castel-Lavilla, María Ángeles, Len, Oscar, Marquez-Algaba, Ester, Nuvials-Casals, Xavier, Martínez González, Daniel, Lacasa, Judith Sacanell, Carratalà, Jordi, Sabé, Nuría |
| المساهمون: |
Instituto de Salud Carlos III |
| المصدر: |
Frontiers in Cellular and Infection Microbiology ; volume 13 ; ISSN 2235-2988 |
| بيانات النشر: |
Frontiers Media SA |
| سنة النشر: |
2023 |
| المجموعة: |
Frontiers (Publisher - via CrossRef) |
| مصطلحات موضوعية: |
Infectious Diseases, Microbiology (medical), Immunology, Microbiology |
| الوصف: |
COVID-19-associated pulmonary aspergillosis (CAPA) has emerged as a frequent complication in the intensive care unit (ICU). However, little is known about this life-threatening fungal superinfection in solid organ transplant recipients (SOTRs), including whether targeted anti-mold prophylaxis might be justified in this immunosuppressed population. We performed a multicentric observational retrospective study of all consecutive ICU-admitted COVID-19 SOTRs between August 1, 2020 and December 31, 2021. SOTRs receiving antifungal prophylaxis with nebulized amphotericin-B were compared with those without prophylaxis. CAPA was defined according the ECMM/ISHAM criteria. Sixty-four SOTRs were admitted to ICU for COVID-19 during the study period. One patient received antifungal prophylaxis with isavuconazole and was excluded from the analysis. Of the remaining 63 SOTRs, nineteen (30.2%) received anti-mold prophylaxis with nebulized amphotericin-B. Ten SOTRs who did not receive prophylaxis developed pulmonary mold infections (nine CAPA and one mucormycosis) compared with one who received nebulized amphotericin-B (22.7% vs 5.3%; risk ratio 0.23; 95%CI 0.032-1.68), but with no differences in survival. No severe adverse events related to nebulized amphotericin-B were recorded. SOTRs admitted to ICU with COVID-19 are at high risk for CAPA. However, nebulized amphotericin-B is safe and might reduce the incidence of CAPA in this high-risk population. A randomized clinical trial to confirm these findings is warranted. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
unknown |
| DOI: |
10.3389/fcimb.2023.1165236 |
| DOI: |
10.3389/fcimb.2023.1165236/full |
| الإتاحة: |
https://doi.org/10.3389/fcimb.2023.1165236Test |
| حقوق: |
https://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: |
edsbas.64F53859 |
| قاعدة البيانات: |
BASE |
